1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Metastatic Prostate Cancer Global Clinical Trials Review, H1, 2014

Metastatic Prostate Cancer Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Metastatic Prostate Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Prostate Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Prostate Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Metastatic Prostate Cancer Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 9
Metastatic Prostate Cancer 9
Report Guidance 9
Clinical Trials by Region 10
Clinical Trials and Average Enrollment by Country 11
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 13
Top Five Countries Contributing to Clinical Trials in Europe 14
Top Countries Contributing to Clinical Trials in North America 15
Top Countries Contributing to Clinical Trials in Middle East and Africa 16
Top Five Countries Contributing to Clinical Trials in Central and South America 17
Clinical Trials by G7 Countries: Proportion of Metastatic Prostate Cancer to Oncology Clinical Trials 18
Clinical Trials by Phase in G7 Countries 19
Clinical Trials in G7 Countries by Trial Status 20
Clinical Trials by E7 Countries: Proportion of Metastatic Prostate Cancer to Oncology Clinical Trials 21
Clinical Trials by Phase in E7 Countries 22
Clinical Trials in E7 Countries by Trial Status 23
Clinical Trials by Phase 24
In Progress Trials by Phase 25
Clinical Trials by Trial Status 26
Clinical Trials by End Point Status 27
Unaccomplished Trials of Metastatic Prostate Cancer 28
Subjects Recruited Over a Period of Time 31
Clinical Trials by Sponsor Type 32
Prominent Sponsors 33
Top Companies Participating in Metastatic Prostate Cancer Therapeutics Clinical Trials 34
Prominent Drugs 36
Latest Clinical Trials News on Metastatic Prostate Cancer 37
Apr 02, 2014: Bayer Initiates Phase 3 Trial of Xofigo (radium Ra 223 dichloride) Injection in Combination with Abiraterone Acetate for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Bone Predominant Metastatic Castration-Resistant Prostate Cancer 37
Jan 30, 2014: Progenics Pharmaceuticals Presents Positive Data From a Phase 2 Trial of PSMA ADC in Patients With Chemotherapy Experienced Metastatic Castrate Resistant Prostate Cancer 37
Jan 28, 2014: Medivation and Astellas Announce Final Results From the Phase 3 PREVAIL Trial of Enzalutamide in Men With Metastatic Prostate Cancer Progressing on Androgen Deprivation Therapy 38
Jun 02, 2012: Zytiga's Phase III Results Show Significant Improvement In Radiographic Progression-Free Survival And Trend For Increased Overall Survival In Metastatic Prostate Cancer Patients 40
Feb 24, 2012: Active Biotech And Ipsen Report Tasquinimod Phase II Long Term Safety Data At 27th European Association Of Urology Congress 41
Clinical Trial Profiles 42
Clinical Trial Overview of Top Companies 42
Johnson and Johnson 42
Clinical Trial Overview of Johnson and Johnson 42
Astellas Pharma Inc. 44
Clinical Trial Overview of Astellas Pharma Inc. 44
AstraZeneca PLC 45
Clinical Trial Overview of AstraZeneca PLC 45
Medivation, Inc. 46
Clinical Trial Overview of Medivation, Inc. 46
Sanofi 47
Clinical Trial Overview of Sanofi 47
Ipsen S.A. 48
Clinical Trial Overview of Ipsen S.A. 48
Bristol-Myers Squibb Company 49
Clinical Trial Overview of Bristol-Myers Squibb Company 49
Pfizer Inc. 50
Clinical Trial Overview of Pfizer Inc. 50
Novartis AG 51
Clinical Trial Overview of Novartis AG 51
Eli Lilly and Company 52
Clinical Trial Overview of Eli Lilly and Company 52
Clinical Trial Overview of Top Institutes / Government 53
National Cancer Institute 53
Clinical Trial Overview of National Cancer Institute 53
European Organization for Research and Treatment of Cancer 56
Clinical Trial Overview of European Organization for Research and Treatment of Cancer 56
Memorial Sloan Kettering Cancer Center 57
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 57
Barbara Ann Karmanos Cancer Institute 58
Clinical Trial Overview of Barbara Ann Karmanos Cancer Institute 58
The University of Texas M. D. Anderson Cancer Center 59
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 59
Southwest Oncology Group 60
Clinical Trial Overview of Southwest Oncology Group 60
OHSU Knight Cancer Institute 61
Clinical Trial Overview of OHSU Knight Cancer Institute 61
Swiss Group for Clinical Cancer Research 62
Clinical Trial Overview of Swiss Group for Clinical Cancer Research 62
National Prostate Cancer Treatment Group 63
Clinical Trial Overview of National Prostate Cancer Treatment Group 63
UNICANCER Group 64
Clinical Trial Overview of UNICANCER Group 64
Five Key Clinical Profiles 65
Appendix 161
Abbreviations 161
Definitions 161
Research Methodology 162
Secondary Research 162
About GlobalData 163
Contact Us 163
Disclaimer 163
Source 164

List of Tables
Metastatic Prostate Cancer Therapeutics, Global, Clinical Trials by Region, 2014* 10
Metastatic Prostate Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 11
Metastatic Prostate Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 12
Metastatic Prostate Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 13
Metastatic Prostate Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 14
Metastatic Prostate Cancer Therapeutics Clinical Trials, North America, Top Countries, 2014* 15
Metastatic Prostate Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 16
Metastatic Prostate Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 17
Proportion of Metastatic Prostate Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 18
Metastatic Prostate Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 19
Metastatic Prostate Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 20
Proportion of Metastatic Prostate Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 21
Metastatic Prostate Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 22
Metastatic Prostate Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 23
Metastatic Prostate Cancer Therapeutics, Global, Clinical Trials by Phase, 2014* 24
Metastatic Prostate Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 25
Metastatic Prostate Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 26
Metastatic Prostate Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 27
Metastatic Prostate Cancer Therapeutics, Global, Withdrawn Clinical Trials, 2014* 28
Metastatic Prostate Cancer Therapeutics, Global, Terminated Clinical Trials, 2014* 29
Metastatic Prostate Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 31
Metastatic Prostate Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 32
Metastatic Prostate Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 33
Metastatic Prostate Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 35
Metastatic Prostate Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36
Metastatic Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson and Johnson, 2014* 42
Metastatic Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Astellas Pharma Inc., 2014* 44
Metastatic Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 45
Metastatic Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Medivation, Inc., 2014* 46
Metastatic Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 47
Metastatic Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Ipsen S.A., 2014* 48
Metastatic Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014* 49
Metastatic Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 50
Metastatic Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 51
Metastatic Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 52
Metastatic Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 53
Metastatic Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2014* 56
Metastatic Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 57
Metastatic Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Barbara Ann Karmanos Cancer Institute, 2014* 58
Metastatic Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 59
Metastatic Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Southwest Oncology Group, 2014* 60
Metastatic Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by OHSU Knight Cancer Institute, 2014* 61
Metastatic Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Swiss Group for Clinical Cancer Research, 2014* 62
Metastatic Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by National Prostate Cancer Treatment Group, 2014* 63
Metastatic Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by UNICANCER Group, 2014* 64

List of Figures
Metastatic Prostate Cancer Therapeutics, Global, Clinical Trials by Region (%), 2014* 10
Metastatic Prostate Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 11
Metastatic Prostate Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 12
Metastatic Prostate Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 13
Metastatic Prostate Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 14
Metastatic Prostate Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 15
Metastatic Prostate Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 16
Metastatic Prostate Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 17
Proportion of Metastatic Prostate Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 18
Metastatic Prostate Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 19
Metastatic Prostate Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 20
Proportion of Metastatic Prostate Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 21
Metastatic Prostate Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 22
Metastatic Prostate Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 23
Metastatic Prostate Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2014* 24
Metastatic Prostate Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 25
Metastatic Prostate Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 26
Metastatic Prostate Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 27
Metastatic Prostate Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 31
Metastatic Prostate Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 32
Metastatic Prostate Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 33
Metastatic Prostate Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 34
Metastatic Prostate Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36
GlobalData Methodology 162

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer: Analytical Tool

Prostate Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Epiomic Epidemiology Series: Prostate Cancer Forecast in 18 Major Markets 2016-2026

Epiomic Epidemiology Series: Prostate Cancer Forecast in 18 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • September 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Prostate Cancer in 18 Major Markets Prostate cancer is one of the most common cancers in men. The prostate, found only in men, is the ...

Prostate cancer- Market Insights, Epidemiology and Market Forecast-2023

Prostate cancer- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Prostate cancer - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.